Scientific Literature & Publications
Our peer-reviewed literature or conference publications are available to read here
All of our product candidates are investigational, meaning they are not yet approved for treatment of any of the diseases being studied.
Infectious Disease Focus Areas
Date Range
Explore
Search
Enterobacteriaceae / 25 Apr 2022
SMT-738: A Novel Small-Molecule Inhibitor of Bacterial Lipoprotein Targeting Enterobacteriaceae
Elena Breidenstein et al. ECCMID 2022
C. difficile infection / 25 Apr 2022
Transcriptomic analysis of the Clostridioides difficile-targeting antimicrobial ridinilazole implicates disruption of energy-generation pathways as its mechanism of action
Clive S Mason et al. ECCMID 2022
C. difficile infection / 15 Oct 2021
Characterization of the DNA binding properties of ridinilazole, a phase III antibiotic for treatment of Clostridioides difficile Infection
C. Mason et al. IDWeek 2021
C. difficile infection / 12 Jul 2021
Metagenomic Analysis of the Differential Impact of Ridinilazole and Vancomycin on the Gut Microbiota in a Phase II Study
E. Duperchy et al. ECCMID 2021
C. difficile infection / 12 Jul 2021
Metagenomic Analysis of the Impact of the Precision Antibiotic Ridinilazole, Compared to Vancomycin, on the Gut Resistome in a Phase II Study
E. Duperchy et al. ECCMID 2021
C. difficile infection / 12 Jul 2021
Identification of the Mechanism of Action for Ridinilazole, a Phase III Antibiotic for Treatment of Clostridioides difficile
T. Avis et al. ECCMID 2021
/ 30 Jun 2021
Microbiome Diversity and Bile Acid Metabolism in Patients With Clostridioides Difficile Infection Treated With Ridinilazole or Vancomycin: Results from a Phase II Study
E. Duperchy et al. IHMC 2021
C. difficile infection / 05 Jan 2021
Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile
D. Collins et al. Journal of Antimicrobial Chemotherapy, dkaa522. 2020
Discuva Platform / 23 Dec 2020
High-density transposon libraries utilising outward-oriented promoters identify mechanisms of action and resistance to antimicrobials
C. Coward et al. FEMS Microbiology Letters, Volume 367, Issue 22. 2020
C. difficile infection / 13 Jul 2020
Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids
X. Qian et al. American Journal of Physiology, Gastrointestinal and Liver Physiology. 2020
C. difficile infection / 07 Oct 2019
Narrow-spectrum antibiotic treatment of Clostridium difficile infection improves preservation of intestinal metabolic profile
K. Yanagi et al. ID Week 2019
C. difficile infection / 03 Oct 2019
Quality of Life Changes in Patients with Clostridium difficile Infection (CDI): A Randomized, Double-Blind Trial of Ridinilazole (RDZ) Compared to Vancomycin (VAN)
S. Paul et al. ID Week 2019